Literature DB >> 17868010

Menstrual migraine: clinical and therapeutical aspects.

Gianni Allais1, Ilaria Castagnoli Gabellari, Cristina De Lorenzo, Ornella Mana, Chiara Benedetto.   

Abstract

Estrogens fluctuations, particularly their premenstrual fall, are currently regarded as the main triggers of menstrual migraine (MM). MM presents in two clinical forms: pure MM, where attacks are confined to the perimenstrual period (PMP), and menstrually related migraine, where attacks always occur during, but are not confined to, the PMP. MM episodes are usually longer, more intense, more disabling and more refractory than nonmenstrual attacks. Acute management of MM should initially be abortive and primarily sought with triptans. If this fails, short-term perimenstrual prophylaxis with NSAIDs, coxibs, triptans or ergotamine derivatives can be considered. Hormone manipulations, mainly application of percutaneous estradiol gel in PMP or administration of oral contraceptives in extended cycles, constitute an alternative approach for nonresponders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868010     DOI: 10.1586/14737175.7.9.1105

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

1.  Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan.

Authors:  Gianni Allais; Giancarlo Acuto; Chiara Benedetto; Giovanni D'Andrea; Licia Grazzi; Gian Camillo Manzoni; Franca Moschiano; Florindo d'Onofrio; Fabio Valguarnera; Gennaro Bussone
Journal:  Neurol Sci       Date:  2010-06       Impact factor: 3.307

2.  A review of the use of frovatriptan in the treatment of menstrually related migraine.

Authors:  Gianni Allais; Chiara Benedetto
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

3.  Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan.

Authors:  Gianni Allais; Gennaro Bussone; Gisella Airola; Paola Borgogno; Ilaria Castagnoli Gabellari; Cristina De Lorenzo; Elena Pavia; Chiara Benedetto
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

4.  Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan.

Authors:  Gianni Allais; Vincenzo Tullo; Chiara Benedetto; Dario Zava; Stefano Omboni; Gennaro Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

5.  Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan.

Authors:  Lidia Savi; Stefano Omboni; Carlo Lisotto; Giorgio Zanchin; Michel D Ferrari; Dario Zava; Lorenzo Pinessi
Journal:  J Headache Pain       Date:  2011-08-13       Impact factor: 7.277

6.  Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.

Authors:  Marco Bartolini; Maria Adelaide Giamberardino; Carlo Lisotto; Paolo Martelletti; Davide Moscato; Biagio Panascia; Lidia Savi; Luigi Alberto Pini; Grazia Sances; Patrizia Santoro; Giorgio Zanchin; Stefano Omboni; Michel D Ferrari; Brigida Fierro; Filippo Brighina
Journal:  J Headache Pain       Date:  2012-05-17       Impact factor: 7.277

Review 7.  Triptans in prevention of menstrual migraine: a systematic review with meta-analysis.

Authors:  Yong Hu; Xiaofei Guan; Lin Fan; Lingjing Jin
Journal:  J Headache Pain       Date:  2013-01-30       Impact factor: 7.277

Review 8.  Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine.

Authors:  Gianni Allais; Chiara Benedetto
Journal:  Drug Des Devel Ther       Date:  2016-10-03       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.